Abstract
According to the US Food and Drug Administration, pharmacometrics is an emerging science that quantifies drugs, diseases, and trial information to aid efficient drug development and/or regulatory decisions. Quantitative decision making occurs at all stages of drug development. In general, patient-level data are not made available to competitors. However, summary-level data are available. Model-based meta-analysis (MBMA) is a powerful tool for decision making which identifies the candidate position in the market. The limitation of MBMA is the heterogeneity of the treatment effect. In the near future, MBMA application is expected at every stage of drug development.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
